What is ACADIA Pharmaceuticals Inc?
, a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 2.96B, and a P/E ratio of 8.3x.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 13,321 shares $69k | 0 |
| 3-6months | 753,521 shares $1.4M | 0 |
| 6-9months | 1225,183 shares $546k | 0 |
| 9-12months | 0 | 0 |